Menu
X
Couple smiling.

CAR-T
therapy for
lymphoma

Immunotherapy enhances the power of a patient’s immune system to attack tumors. An immunotherapy approach, called chimeric antigen receptor (CAR) T-cell therapy, uses patients’ own immune cells to treat their cancer

What Is CAR T Cell Therapy?

CAR T cell therapy provides engineered molecules called chimeric antigen receptors (CARs) that recognize and destroy antigens present on the surface of lymphoma cells. T cells are removed from patients and genetically modified to produce CARs. The genetically engineered CAR T cells are grown in the laboratory until they number in the billions and are then infused back into the patient.

How Does CAR T-cell Therapy Work?

In CAR T-cell therapy for lymphoma, a lab modifies a patient's blood cells to help them fight cancer cells in the blood. Once a patient's blood is drawn, a lab engineers the T-cells to gain a chimeric antigen receptor (CAR), which can bind to a protein on the cancer cells. The CAR T-cells are multiplied to produce more engineered T-cells. When there are enough of these special cells, they are reintroduced to the patient via a blood infusion.malignant plasma cells then produce an abnormal antibody called M protein, high levels of which are a hallmark characteristic of multiple myeloma.

Diagram of bone structure, plasma cells, and multiple myeloma cells.

Approved CAR T Cell Therapies in Lymphoma

Approved CAR T Cell therapies include:

Approved drug Approved drug indication
Axicabtagene Ciloleucel (Yescarta)
  • Treatment targeting CD19 for patients with certain types of relapsed/refractory large B-cell lymphoma after at least two other kinds of treatment. (DLBCL not otherwise specified; primary mediastinal large B-cell lymphoma; high-grade B-cell lymphoma; DLBCL arising from FL).
  • For the treatment of adult patients with relapsed or refractory follicular lymphoma (FL) after two or more lines of systemic therapy
Brexucabtagene Autoleucel (Tecartus)
  • Treatment targeting CD19 for patients with relapsed or refractory mantle cell lymphoma (MCL).
  • Lisocabtagene Maraleucel (Breyanzi)
    • Treatment targeting CD19 for patients with certain types of large B-cell lymphoma, including diffuse large B-cell lymphoma (DLBCL) not otherwise specified (including DLBCL arising from indolent lymphoma), high-grade B-cell lymphoma, primary mediastinal large B-cell lymphoma, and follicular lymphoma grade 3B, who have not responded to, or who have relapsed after, at least two other types of systemic treatment.
    Tisagenlecleucel (Kymriah)
    • Treatment targeting CD19 for patients with certain types of relapsed/refractory large B-cell lymphoma after two or more lines of systemic therapy. (DLBCL not otherwise specified; high grade B-cell lymphoma; DLBCL arising from FL)

    CAR T Cell Process

    1. Leukapheresis

    Your T cells are obtained through a process called leukapheresis, which usually takes three to four hours.

    2. T-Cell Engineering

    The T cells are sent to a processing center where they are genetically engineered to target your lymphoma.

    3. CAR T Cell Transport

    Once enough of the CAR-T cells are available at the processing center, the cells are frozen for transport to your certified treatment center.

    4. Lymphodepleting Chemotherapy

    A few days prior to your CAR-T cell infusion, you will receive low-dose chemotherapy.

    5. CAR T Cell Infusion

    A few days after completing chemotherapy, you will receive your CAR-T cells at your certified treatment center.

    6. CAR T Cells Attack the Lymphoma

    Once the CAR-T cells enter your body, they begin to multiply and attack the lymphoma cells.

    By using our site, you agree to our Terms and Conditions and Privacy Policy.Advanced Medicine In China does not provide medical advice, diagnosis, or treatment. The information provided on this site is designed to support, not replace, the relationship that exists between a patient/site visitor and his/her existing physician.

    © Copyright 2023 Advanced Medicine In China. All rights reserved.